Aurinia Pharmaceuticals Inc (AUPH) : Abingworth Llp added new position in Aurinia Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 88,307 shares of Aurinia Pharmaceuticals Inc which is valued at $191,626 , the company said in a statement filed on May 13, 2016 with the SEC.Aurinia Pharmaceuticals Inc makes up approximately 0.22% of Abingworth Llp’s portfolio.
Other Hedge Funds, Including , Renaissance Technologies reduced its stake in AUPH by selling 6,800 shares or 18.28% in the most recent quarter. The Hedge Fund company now holds 30,400 shares of AUPH which is valued at $65,968.
Aurinia Pharmaceuticals Inc opened for trading at $2.5 and hit $2.61 on the upside on Wednesday, eventually ending the session at $2.57, with a gain of 1.58% or 0.04 points. The heightened volatility saw the trading volume jump to 7,709 shares. Company has a market cap of $83 M.
Aurinia Pharmaceuticals Inc. (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate voclosporin which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug administered twice daily. It is structurally similar to cyclosporine A (CsA) but is chemically modified on the amino acid-1 residue. Voclosporin is used as a treatment for lupus nephritis (LN). LN is an inflammation of the kidney that if untreated or inadequately treated can lead to end-stage renal disease the requirement for life-long dialysis or death. The Company had completed two Phase III studies of voclosporin in patients with moderate to severe psoriasis. The Company had completed a Phase IIb clinical trial of voclosporin in de novo renal transplant recipients. The Company’s wholly owned subsidiaries include Aurinia Pharmaceuticals Inc. and Aurinia Pharma Limited.